Baxter International shares are down about 3% in Tuesday trading (April 28, 2026) as investors reduce risk heading into the company’s first-quarter 2026 results, scheduled for before the market opens on Thursday, April 30. With the stock trading near its recent lows and sentiment already fragile after earlier guidance and operational challenges, even modest pre-earnings repositioning can pressure shares. (marketbeat.com)

Market expectations center on a Q1 print of roughly $0.32 in EPS on about $2.62 billion in revenue, while Baxter’s FY 2026 adjusted EPS guidance has been set at $1.85–$2.05. With the reporting date close, the selloff looks consistent with traders and some longer-term holders stepping aside until they see updated commentary on demand trends and margin recovery. (marketbeat.com)

An amended Schedule 13G/A dated April 27, 2026 shows BlackRock reporting beneficial ownership of 33,109,852 shares, or 6.4% of Baxter’s common stock (cover date March 31, 2026). The filing is a passive ownership disclosure update and does not, by itself, indicate a control or activist agenda—yet it can still draw attention on a down day as the market debates whether large holders are accumulating, rebalancing, or simply updating required reporting. (stocktitan.net)

Baxter remains highly levered relative to its recent history and has faced operational overhangs that have weighed on confidence, including issues tied to infusion-pump availability and hospital IV-solution dynamics that have been expected to extend into 2026. Those themes heighten the importance of near-term execution updates and any changes to debt-reduction pacing, which can amplify volatility into earnings. (investing.com)